This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Neumora Therapeutics IPO Class Action
Business class action

Neumora Therapeutics IPO Class Action

Analysis based on 17 articles · First reported Feb 07, 2025 · Last updated Feb 22, 2025

Sentiment
-20
Attention
2
Articles
17
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Neumora Therapeutics could lead to a decline in its stock price due to potential financial liabilities and damage to investor confidence. This event highlights the risks associated with initial public offerings and the importance of accurate disclosure for publicly traded companies.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has filed a class action lawsuit against Neumora Therapeutics, alleging that the company made false and misleading statements in its September 2023 IPO Offering Documents. The lawsuit claims that Neumora Therapeutics amended BlackThorn Therapeutics' Phase Two Trial inclusion criteria and added a prespecified analysis to justify its Phase Three Program for Navacaprant, a treatment for major depressive disorder. Furthermore, the lawsuit asserts that the Phase Two Trials lacked adequate data to accurately predict the results of the KOASTAL-1 study. Investors who purchased Neumora Therapeutics common stock in the IPO are encouraged to join the class action, with an April 7, 2025, deadline to move for lead plaintiff.

Key Actions
100 Rosen Law Firm filed class action lawsuit Neumora Therapeutics
70 Neumora Therapeutics amended trial criteria BlackThorn Therapeutics
60 Neumora Therapeutics added prespecified analysis
Entities Involved
priv
Neumora Therapeutics
Neumora Therapeutics is the defendant in a class action lawsuit alleging false and misleading statements in its IPO Offering Documents, which could lead to significant financial penalties and reputational damage.
Importance 100.0 Sentiment -50.0
priv
BlackThorn Therapeutics
BlackThorn Therapeutics' original Phase Two Trial inclusion criteria were allegedly amended by Neumora Therapeutics to justify its Phase Three Program, which is a key point in the class action lawsuit.
Importance 30.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
Relationships
Neumora Therapeutics acquirer ↔ BlackThorn Therapeutics Neumora Therapeutics acquired BlackThorn Therapeutics in September 2020, integrating its clinical pipeline and taking ov
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen founding partner ↔ Philip Kim Lawrence Rosen is a founding partner of the Rosen Law Firm, where he directs attorneys including Philip Kim. Together, t
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.